Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor

Bayer Clinical Trials
31 Jan, 2020 ,

This is the first study where BAY1163877 is given to humans. Impact of the study is to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor. Patients (all comers) will receive the study drug treatment in a dose-escalation scheme (no placebo group) to determine the safety, tolerability and maximum tolerated dose (MTD) of BAY1163877.